Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nike Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Nike Inc trades at $41.24 (market cap $62.47B). The key difference: Nike Inc is far larger — about 72.3× Amphastar Pharmaceuticals Inc's market cap, and Nike Inc pays a 3.89% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NKE | |
|---|---|---|
Market Cap | $863.95M | $62.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $79.17 |
52-Week Low | $16.87 | $40.75 |
Enterprise Value | $1.26B | $64.48B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Nike (NKE) trades at $41.32, down 0.91% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong profitability with a 42.91% gross margin and 22.14% ROE, but revenue declined to $46.31B in 2025. Recent quarters have consistently beaten EPS estimates, with Q1 2026 EPS of $0.72 significantly exceeding expectations. Analysts maintain a consensus Buy rating with a $50.45 price target, indicating potential upside from current levels.
The outlook balances solid brand strength and earnings beats against revenue headwinds and competitive pressures. Investment opportunity lies in valuation discount to analyst targets and operational discipline, but risks include sluggish demand in key markets like China and margin compression from promotional activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
